Benjamin J. Hickey, Senior Vice President, Chief Commercial Officer

Mr. Hickey brings to Halozyme a long track record of leading commercial teams, including launch teams, for innovative oncology treatments. Mr. Hickey joined Halozyme in September 2018 as Senior Vice President, Chief Commercial Officer. He is responsible for the global commercial strategy for the company’s current and future oncology portfolio.

Prior to Halozyme Mr. Hickey served as the General Manager, UK & Ireland at Bristol-Myers Squibb overseeing an organization of more than 300 people across the virology, immuno-science, oncology and cardiovascular disease businesses. Throughout his 17-year career with Bristol-Myers Squibb, he held roles of increasing responsibility, including serving as Vice President Marketing, Immuno-Oncology where he led the commercialization of Yervoy® and oversaw the launch preparedness of Opdivo® across more than eight indications and Executive Director and Vice President, Hematology, responsible for all commercial activity for Sprycel®, Erbitux® and an investigational multiple myeloma asset. In addition, he served as the U.S. brand lead for Farxiga® which is used to help treat type 2 diabetes and held positions in U.S. Finance and U.S. and worldwide access and reimbursement.

Mr. Hickey received his B.S. in Management and his MBA from St. Johns University in Queens, New York.


You are now leaving Halozyme is not responsible for or endorses the content of the linked site.